RxDoctor Payments DataLook up a doctor →

Erick Calderon

Cardiology · Lakewood Ranch, FLNPI 1912904855

Payments from drug & device makers

$12,095in general payments, 2019–2025

Across 434 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$2K
  • Amgen$1K
  • Penumbra, Inc.$1K
  • AstraZeneca$823
  • Boston Scientific$748
  • Inari Medical, Inc.$682
  • plus $5K from 40 others

What the payments were for

  • Travel & lodging$3263%
  • Food & beverage$9,77395%
  • Education$1832%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,095 in reported general payments places this provider in the 85th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,033,323
Medicare patients
901
Services billed
7,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban233$270,598
EliquisApixaban172$185,467
EntrestoSacubitril/Valsartan68$114,268
JardianceEmpagliflozin62$90,626
Repatha SyringeEvolocumab56$57,892
FarxigaDapagliflozin Propanediol36$51,256
Repatha SureclickEvolocumab55$47,583
MultaqDronedarone Hcl18$25,962
BrilintaTicagrelor25$23,543
VascepaIcosapent Ethyl18$16,181
Rosuvastatin Calcium1,017$14,083
Metoprolol Succinate887$12,956
Praluent PenAlirocumab13$9,692
Flecainide Acetate170$8,607
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide618$8,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$480$270,598233 claims
PfizerEliquis$139$185,467172 claims
NovartisEntresto$387$114,26868 claims
Boehringer IngelheimJardiance$419$90,62662 claims
AstraZenecaFarxiga, Brilinta$823$74,80061 claims
Sanofi-aventis U.S. LLCMultaq$261$25,96218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 cardiology providers in Florida.

Other cardiology in Lakewood Ranch

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →